22 results
10-K
2020 FY
NRIX
Nurix Therapeutics Inc
16 Feb 21
Annual report
4:11pm
in culture with NX-0255. Although NX-0255 has limited oral bioavailability, we have demonstrated inhibition of CBL-B both biochemically and in ex vivo T cell … culture, making it well suited for the ex vivo creation of new ACT products. DeTIL-0255 is designed to be a single administration autologous TIL
S-1
NRIX
Nurix Therapeutics Inc
2 Jul 20
IPO registration
4:04pm
culture.
We may seek to establish additional collaborations. If we are not able to establish collaborations on commercially reasonable terms, we may … such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties
DRS/A
NRIX
Nurix Therapeutics Inc
10 Jun 20
Draft registration statement (amended)
12:00am
the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture.
We may seek … them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new drugs
424B4
1kniq6pqv6 k55
24 Jul 20
Prospectus supplement with pricing info
4:06pm
S-1/A
gvdr8ls
20 Jul 20
IPO registration (amended)
6:32am
DRS
bieuebq5ybtif
5 May 20
Draft registration statement
12:00am
10-Q
a4ok2rx8x3
14 Oct 20
Quarterly report
4:02pm